Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

Rare Disease Therapeutics - Jobs & Pipeline | Formulate

Companies
Rare Disease Therapeutics

Rare Disease Therapeutics

TN - FranklinBiotechnology

Website LinkedIn Careers Page

Focus: Rare Disease Therapeutics is a private biotechnology company founded in 1991 specializing in antivenoms and rare disease products, operating at a modest scale from Franklin, Tennessee.

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PRIVATE

Open Jobs

0

About Rare Disease Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Rare Disease Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Training program

Myotonic Dystrophy 1

N/A

Clinical Trials (1)

NCT05400629Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1

N/A

Help build intelligence for Rare Disease Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused niche in rare diseases and antivenoms offers deep specialization and potential for meaningful impact on underserved patient populations
33-year operating history suggests organizational stability and persistence in a difficult therapeutic area
Private structure may enable flexibility in decision-making and closer collaboration across functional teams

Watch Out For

Zero active clinical trials and no disclosed pipeline programs create significant uncertainty about current R&D momentum and product potential
Private status with no disclosed funding, revenue, or employee count raises questions about financial viability and growth trajectory

Generated by Claude from Rare Disease Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Krabbe Disease Global Patient Registry

N/A

Clinical Trials (1)

NCT02993796Krabbe Disease Global Patient Registry

N/A

Chromium Contamination of Parenteral Nutrition

Trace Element Excess

N/A

Clinical Trials (1)

NCT03906890Chromium Contamination of Parenteral Nutrition

N/A

Venipuncture

N/A

Clinical Trials (1)

NCT06210698Angioedema Biomarker Research Study

N/A

Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

N/A

Clinical Trials (1)

NCT02994303Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

N/A

Comparing Body Composition Assessment Methods

Body Composition

N/A

Clinical Trials (1)

NCT04610918Comparing Body Composition Assessment Methods

N/A

A Natural History Study of the Gangliosidoses

Tay-Sachs Disease

N/A

Clinical Trials (1)

NCT00668187A Natural History Study of the Gangliosidoses

N/A

Markers of Bone Disease in Children on Parenteral Nutrition

Metabolic Bone Disease

N/A

Clinical Trials (1)

NCT01603472Markers of Bone Disease in Children on Parenteral Nutrition

N/A

Limb-Girdle Muscular Dystrophy Type 2I in Norway

Limb Girdle Muscular Dystrophy, Type 2I

N/A

Clinical Trials (1)

NCT03930628Limb-Girdle Muscular Dystrophy Type 2I in Norway

N/A

Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research C

Erythropoietic Protoporphyria (EPP)

N/A

Clinical Trials (1)

NCT01880983Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))

N/A

Protein intake

Phenylketonuria

N/A

Clinical Trials (1)

NCT01965691Protein Requirements in Children With Phenylketonuria (PKU)

N/A

MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

Mucopolysaccharidosis Type I

N/A

Clinical Trials (1)

NCT03576729MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

N/A

Simple Breath Test to Examine Phenylalanine Metabolism

Phenylketonuria (PKU)

N/A

Clinical Trials (1)

NCT02009904Simple Breath Test to Examine Phenylalanine Metabolism

N/A

Engagement in Physical Activities and Sports in Adolescents With Diaphragmatic Hernia

Congenital Diaphragmatic Hernia

N/A

Clinical Trials (1)

NCT05666986Engagement in Physical Activities and Sports in Adolescents With Diaphragmatic Hernia

N/A

Energy Requirements in Mitochondrial Disease

Mitochondrial Disease

N/A

Clinical Trials (1)

NCT01776918Energy Requirements in Mitochondrial Disease

N/A

Longitudinal Studies of Brain Structure and Function in MPS Disorders

Mucopolysaccharidosis Type I

N/A

Clinical Trials (1)

NCT01870375Longitudinal Studies of Brain Structure and Function in MPS Disorders

N/A

MuSK Myasthenia 1000 Study

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT06259071MuSK Myasthenia 1000 Study

N/A

CRD-TMH-001

Duchenne Muscular Dystrophy

Phase 1

Clinical Trials (1)

NCT05514249Treatment of a Single Patient With CRD-TMH-001

Phase 1

ANAWIDOW [antivenin latrodectus

Phase 1

Clinical Trials (1)

NCT04848714Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions

Phase 1

N-acetylcysteine

Gaucher Disease Type 1

Phase 2

Clinical Trials (1)

NCT02583672Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

Phase 2

Analatro

Phase 3

Clinical Trials (1)

NCT00657540Black Widow Spider Antivenin for Patients With Systemic Latrodectism

Phase 3

Rifampicin

Multiple System Atrophy

Phase 3

Clinical Trials (1)

NCT01287221Study of Rifampicin in Multiple System Atrophy

Phase 3

miglustat

GM1 Gangliosidoses

Phase 4

Clinical Trials (1)

NCT02030015Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Phase 4

Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]

Duchenne Muscular Dystrophy

Phase 4

Clinical Trials (1)

NCT04708314An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1991

Portfolio: 24 clinical trials

Top TAs: Rare Diseases, Dermatology, Gastroenterology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

6 pipeline

1 pipeline

Gastroenterology

1 pipeline

1 pipeline

Marketed

Pipeline